However, several clinical indications suggest that EGFR-mutant lung cancers maintain partial sensitivity to TKIs despite development of acquired resistance and tumors can still be sensitive to EGFR-TKIs treatment beyond progression [19–22] or re-treatment at further progression [23–25]. This evidence concerns the gene EGFR and lung cancer.